Candriam S.C.A. Replimune Group, Inc. Transaction History

Candriam S.C.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	SELL	$15.65 - $24.1 $793,908 - $1.22 Million	-50,729 Reduced 7.65%	612,193 $14.2 Million
Q4 2022 Feb 13, 2023	BUY	$17.09 - $27.91 $911,751 - $1.49 Million	53,350 Added 8.75%	662,922 $18 Million
Q3 2022 Nov 10, 2022	BUY	$15.6 - $21.15 $1.83 Million - $2.48 Million	117,068 Added 23.77%	609,572 $10.5 Million
Q1 2022 May 13, 2022	SELL	$15.24 - $29.75 $411,601 - $803,488	-27,008 Reduced 5.2%	492,504 $8.36 Million
Q4 2021 Feb 10, 2022	SELL	$25.43 - $34.25 $66,855 - $90,043	-2,629 Reduced 0.5%	519,512 $14.1 Million
Q3 2021 Nov 09, 2021	BUY	$28.98 - $39.54 $1.05 Million - $1.43 Million	36,153 Added 7.44%	522,141 $15.5 Million
Q2 2021 Jul 20, 2021	BUY	$28.5 - $39.37 $9.23 Million - $12.7 Million	323,828 Added 199.7%	485,988 $18.7 Million
Q1 2021 Apr 29, 2021	BUY	$30.22 - $45.57 $181 - $273	6 Added 0.0%	162,160 $5.94 Million
Q4 2020 Jan 22, 2021	BUY	$23.5 - $52.65 $3.81 Million - $8.54 Million	162,154 New	162,154 $6.19 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $693M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.